PF4 Autoantibody Complexes Cause Activation of Integrins αIIbβ3 and αvβ3 and Possible Subsequent Thrombosis and Autoimmune Diseases.

Previous studies suggest that multiple inflammatory chemokines (e.g., CCL5, CXCL12) bind to the allosteric site of integrins (site 2) and induce allosteric integrin activation and inflammatory signals. PF4 is abundantly present in platelet granules, but PF4 levels are very low in plasma. PF4 is released from damaged platelets and is markedly increased in plasma (>1000×) in pathological conditions. PF4 (tetramer) is an inhibitory chemokine, and the specifics of PF4 signaling are unclear. Docking simulation predicted that PF4 monomer binds to site 2, but PF4 by itself did not induce allosteric integrin activation. Anti-PF4 mAbs KKO and RTO generate complexes with PF4 tetramer and monomer, respectively. We discovered that the PF4/RTO complex induced potent integrin activation, but the PF4/KKO complex did not. We hypothesize that inactive PF4 tetramer is converted by RTO to active monomer. A PF4 mutant (4E), in which four basic amino acid residues in the predicted site 2 binding site were mutated to Glu, did not induce integrin activation and acted as a dominant-negative antagonist, suggesting that the RTO/PF4 complex is required to bind to site 2 for integrin activation. Notably, RTO-like autoantibody was detected in plasma of healthy people. We propose that autoanti-PF4 in healthy controls may not be a problem since plasma PF4 levels are very low. When plasma PF4 tetramer is increased, active PF4 monomer is generated by autoanti-PF4 and plays a role in disease pathogenesis. Notably, anti-inflammatory cytokine neuregulin-1 and anti-inflammatory ivermectin bind to site 2 and suppress integrin activation induced by RTO/PF4 complex, suggesting that neuregulin-1 and ivermectin are potentially useful to suppress PF4/anti-PF4-mediated inflammatory signals.